Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5164-5180

  Majhi, Arnab ^a   Adhikary, Rana ^a   Bhattacharyya, Aritra ^a   Mahanti, Sayantika ^a   Bishayi, Biswadev ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AUTOLYSIN; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GAMMA INTERFERON; GENTAMICIN; IMIPENEM; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEVOFLOXACIN; MEROPENEM; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NITRIC OXIDE; OXACILLIN; PENICILLIN DERIVATIVE; PNEUMOLYSIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; N ACETYLMURAMOYLALANINE AMIDASE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN; VIRULENCE FACTOR;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BLOOD VESSEL PERMEABILITY; BROTH DILUTION; CELL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; INFLAMMATORY CELL; LUNG LAVAGE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TISSUE HOMOGENATE; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTEREMIA; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; MALE; METABOLISM; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS; PNEUMONIA; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CEFTRIAXONE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; LEVOFLOXACIN; MALE; MICE; MICE, INBRED BALB C; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PNEUMOCOCCAL INFECTIONS; PNEUMONIA; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VIRULENCE; VIRULENCE FACTORS;

EID: 84906080622     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03245-14     Document Type: Article

References (72)

1. Aspa J, Rajas O, de Castro FR. 2008. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin. Pharmacother. 9:229-241. http://dx.doi.org/10.1517/14656566.9.2. 229. (Pubitemid 351233731)
2. Neill DR, Fernandes VE, Wisby L, Haynes AR, Ferreira DM, Laher A, Strickland N, Gordon SB, Denny P, Kadioglu A, Andrew PW. 2012. T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog. 8:1-12. http://dx.doi.org/10.1371/journal.ppat.1002660.
3. Meijvis SC, Grutters JC, Thijsen SF, Rijkers GT, Biesma DH, Endeman H. 2011. Therapy in pneumonia: what is beyond antibiotics? Neth. J. Med. 69:21-26.
4. Waterer GW, Somes GW, Wunderink RG. 2001. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 161:1837-1842. http://dx.doi.org/10.1001/archinte.161.15.1837.
5. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, Tremblay J. 2004. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can. Respir. J. 11:589-593. (Pubitemid 40089898)
6. Waterer GW. 2005. Optimal antibiotic treatment in severe pneumococcal pneumonia-time for real answers. Eur. J. Clin. Microbiol. Infect. Dis. 24:691-692. http://dx.doi.org/10.1007/s10096-005-0019-5. (Pubitemid 41667058)
7. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC, International Pneumococcal Study Group. 2004. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 170:440-444. http://dx.doi.org/10.1164/rccm.200311- 1578OC. (Pubitemid 39214620)
8. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr, Musher DM, Whitney C, Infectious Diseases Society of America. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433. http://dx.doi.org/10.1086/380488. (Pubitemid 37494668)
9. Waterer GW, Rello J. 2006. Choosing the right combination therapy in severe community-acquired pneumonia. Crit. Care 10:115. http://dx.doi.org/10. 1186/cc3976.
10. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. 2007. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 51:3977-3982. http://dx.doi.org/10. 1128/AAC.00006-07. (Pubitemid 350057796)
11. Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J. 2006. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acids substitutions in QRDRs of gyrase A and topoisomerase IV. J. Antimicrob. Chemother. 58:1279-1282. http://dx.doi.org/10.1093/jac/dkl427. (Pubitemid 44884153)
12. Feldman C. 2004. Appropriate management of lower respiratory tract infections in primary care. Prim. Care Respir. J. 13:159-166. http://dx.doi.org/10.1016/j.pcrj.2004.02.006. (Pubitemid 39180792)
13. Ambrose PG, Bast D, Doern GV, Iannini PB, Jones RN, Klugman KP, Low DE. 2004. Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin. Infect. Dis. 39:1554-1556. http://dx.doi.org/10.1086/425508.
14. Sauve C, Azoulay-Dupuis E, Moine P, Darras-Joly C, Rieux V, Carbon C, Bédos JP. 1996. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2829-2834. (Pubitemid 26404353)
15. Flatz L, Cottagnoud M, Kühn F, Entenza J, Stucki A, Cottagnoud P. 2004. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J. Antimicrob. Chemother. 53:305-310. http://dx.doi.org/10.1093/ jac/dkh082. (Pubitemid 38239966)
16. Drago L, Nicola L, Rodighiero V, Larosa M, Mattina R, De Vecchi E. 2011. Comparative evaluation of synergy of combinations of β-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae. J. Antimicrob. Chemother. 66:845-849. http://dx.doi.org/10.1093/jac/dkr016.
17. Gross ME, Giron KP, Septimus JD, Mason EO, Jr, Musher DM. 1995. Antimicrobial activities of β-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob. Agents Chemother. 39:1166-1168. http://dx.doi.org/10.1128/AAC.39.5.1166.
18. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America, American Thoracic Society. 2007. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl 2):S27-S72. http://dx.doi.org/10.1086/511159. (Pubitemid 46290553)
19. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society. 2001. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Res. Crit. Care Med. 163:1730-1754. http://dx.doi.org/10.1164/ajrccm.163.7. at1010.
20. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG. 1998. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect. Immun. 66:912-922. (Pubitemid 28101126)
21. Moncada S, Higgs EA. 1995. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1319-1330.
22. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. 1994. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc. Natl. Acad. Sci. U. S. A. 91:2046-2050. http://dx.doi.org/10.1073/pnas.91.6.2046. (Pubitemid 24092039)
23. Salvemini D, Seibert K, Marino MH. 1996. New concepts in inflammation and therapy. Drug News Perspect. 9:204-219. (Pubitemid 26225522)
24. Andrew PW, Boulnois GJ, Mitchell TJ, Lee CJ, Paton JC, Poolman JT, Peeters CCAM. 1994. Pneumococcal vaccines. Zentralbl. Bakteriol. Suppl. 24:453-466.
25. Marriott HM, Mitchell TJ, Dockrell DH. 2008. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr. Mol. Med. 8:497-509. http://dx.doi.org/10.2174/156652408785747924.
26. Nombela C. 1984. Microbial cell wall synthesis and autolysis. Elsevier Press, Amsterdam, The Netherlands.
27. Paton JC, Andrew PW, Boulnois GJ, Mitchell TJ. 1993. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu. Rev. Microbiol. 47:89-115. http://dx.doi.org/10.1146/annurev.mi. 47.100193.000513. (Pubitemid 23302929)
28. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. 1989. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect. Immun. 57:2037-2042. (Pubitemid 19186880)
29. Berry AM, Lock RA, Hansman D, Paton JC. 1989. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect. Immun. 57:2324-2330. (Pubitemid 19183838)
30. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - 6th ed. NCCLS document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
31. Jain SN, Vishwanatha T, Reena V, Divyashree BC, Aishwarya S, Siddhalingeshwara KG, Venugopal N, Ramesh I. 2011. Antibiotic synergy test: checkerboard method on multidrug resistant Pseudomonas aeruginosa. Int. Res. J. Pharm. 2:196-198.
32. Odds FC. 2003. Synergy, antagonism, and what the checkerboard puts between them. J. Antimicrob. Chemother. 52:1. http://dx.doi.org/10.1093/jac/ dkg301. (Pubitemid 36850074)
33. Eliopoulos GM, Moellering R. 1996. Antimicrobial combinations, p 330-336. In Lorian V (ed), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, MD.
34. Majhi A, Kundu K, Adhikary R, Banerjee M, Mahanti S, Basu A, Bishayi B. 2014. Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice. J. Inflamm. 11:5. http://dx.doi.org/10.1186/1476-9255-11- 5.
35. Ogunniyi AD, Giammarinaro P, Paton JC. 2002. The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo. Microbiology 148:2045-2053. (Pubitemid 34785289)
36. Gisselsson-Solén M, Bylander A, Wilhelmsson C, Hermansson A, Melhus A. 2007. The Binax NOW test as a tool for diagnosis of severe acute otitis media and associated complications. J. Clin. Microbiol. 45:3003-3007. http://dx.doi.org/10.1128/JCM.00299-07. (Pubitemid 47417347)
37. McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, Jackson GW, Beninga KK, Astorga A, McCleskey FK, Huff WB, Niemeyer D, Lohman KL. 2001. Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR. J. Clin. Microbiol. 39:3446-3451. http://dx.doi.org/10.1128/JCM.39.10.3446-3451.2001. (Pubitemid 32954483)
38. Sakai F, Talekar SJ, Klugman KP, Vidal JE, Investigators Group. 2013. Expression of Streptococcus pneumoniae virulence-related genes in the nasopharynx of healthy children. PLoS One 8:e67147. http://dx.doi.org/10.1371/ journal.pone.0067147.
39. Duong M, Simard M, Bergeron Y, Bergeron MG. 2001. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob. Agents Chemother. 45:252-262. http://dx.doi.org/10.1128/AAC.45.1.252-262.2001. (Pubitemid 32039123)
40. Azoulay-Dupuis E, Bédos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Péchère JC, Fantin B, Köhler T. 2004. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob. Agents Chemother. 48:765-773. http://dx.doi.org/10.1128/AAC.48.3.765-773.2004. (Pubitemid 38280322)
41. Wang E, Bergeron Y, Bergeron MG. 2005. Ceftriaxone pharmacokinetics in interleukin-10 treated murine pneumococcal pneumonia. J. Antimicrob. Chemother. 55:721-726. http://dx.doi.org/10.1093/jac/dki085. (Pubitemid 40691852)
42. Simon HJ, Yin EJ. 1970. Microbioassay antimicrobial agents. Appl. Microbiol. 19:573-579.
43. Täuber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA. 1985. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 27:340-342. http://dx.doi.org/10.1128/AAC.27.3.340. (Pubitemid 15144696)
44. Peterson LR, Gerding DN. 1980. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Rev. Infect. Dis. 2:340-348. http://dx.doi.org/10.1093/clinids/ 2.3.340.
45. Greenblatt DJ, Koch-Weser J. 1975. Clinical pharmacokinetics. N. Engl. J. Med. 297:702-705.
46. Nandi D, Mishra MK, Basu A, Bishayi B. 2010. Protective effects of interleukin-6 in lipopolysaccharide (LPS)-induced experimental endotoxemia are linked to alteration in hepatic anti-oxidant enzymes and endogenous cytokines. Immunobiology 215:443-451. http://dx.doi.org/10.1016/j.imbio.2009.08.003.
47. Green TP, Johnson DE, Marchessault RP, Gatto CW. 1988. 1988. Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine. J. Lab. Clin. Med. 111:73-83.
48. Mahanti S, Majhi A, Chongder S, Dutta K, Basu A, Bishayi B. 2013. Increased resistance of immobilized-stressed mice to infection: correlation with behavioral alterations. Brain Behav. Immun. 28:115-127. http://dx.doi.org/10. 1016/j.bbi.2012.11.001.
49. van der Poll T, Opal SM. 2009. Pathogenesis, treatment and prevention of pneumococcal pneumonia. Lancet 374:1543-1556. http://dx.doi.org/10.1016/S0140- 6736(09)61114-4.
50. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750. http://dx.doi.org/10.1056/ NEJMoa012122. (Pubitemid 34983995)
51. Blasi F, Bulfoni A, Concia E, Costantino S, Giusti M, Iori I, Mazzei T, Schito GC. 2010. Attualità nella gestione delle infezioni delle basse vie respiratorie in medicina interna. Ital. J. Med. 4:1-78. (In Italian.)
52. Cottagnoud P, Acosta F, Cottagnoud M, Neftel K, Täuber MG. 2000. Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob. Agents Chemother. 44:2179-2181. http://dx.doi.org/10.1128/AAC.44.8.2179-2181.2000. (Pubitemid 30484447)
53. MacGowan AP, Wootton M, Hedges AJ, Bowker KE, Holt HA, Reeves DS. 1996. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, aminoglycoside and fluoroquinolone. J. Antimicrob. Chemother. 38:193-203. http://dx.doi.org/10.1093/jac/38.2.193. (Pubitemid 26302580)
54. Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG. 2011. Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. Drug Healthc. Patient Saf. 3:59-68. http://dx.doi.org/10.2147/DHPS.S15599.
55. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:101-119. http://dx.doi.org/10.2165/00003088-199732020- 00002. (Pubitemid 27104410)
56. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. 2003. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51:1323-1325. http://dx.doi.org/10.1093/jac/dkg255. (Pubitemid 36748918)
57. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10. http://dx.doi.org/10.1086/516284.
58. Anderson R, Tintinger G, Cockeran R, Potjo M, Feldman C. 2010. Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system. Pharmaceuticals 3:1694-1710. http://dx.doi.org/10.3390/ ph3051694.
59. van der Flier M, Coenjaerts F, Kimpen JLL, Hoepelman AM, Geelen SP. 2000. Streptococcus pneumoniae induces secretion of vascular endothelial growth factor by human neutrophils. Infect. Immun. 68:4792-4794. http://dx.doi.org/10. 1128/IAI.68.8.4792-4794.2000. (Pubitemid 30497759)
60. Volanakis JE. 2001. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38:189-197. http://dx.doi.org/10.1016/S0161-5890(01) 00042-6. (Pubitemid 32786776)
61. Agrawal A. 2005. CRP after 2004. Mol. Immunol. 42:927-930. http://dx.doi.org/10.1016/j.molimm.2004.09.028. (Pubitemid 40489018)
62. Volanakis JE, Kaplan MH. 1971. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136:612-614. http://dx.doi.org/10.3181/00379727-136-35323.
63. Suresh MV, Singh SK, Ferguson DA, Jr, Agrawal A. 2006. Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from Streptococcus pneumoniae infection. J. Immunol. 176:4369-4374. http://dx.doi.org/10.4049/jimmunol.176.7.4369. (Pubitemid 44264417)
64. Canvin JR, Marvin AP, Sivakumaran M, Paton JC, Boulnois GJ, Andrew PW, Mitchell TJ. 1995. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J. Infect. Dis. 172:119-123. http://dx.doi.org/10.1093/infdis/172.1.119.
65. Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hansman D, Paton JC. 1995. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 63:1969-1974.
66. del Mar Garcia-Suarez M, Cima-Cabal MD, Flórez N, García P, Cernuda-Cernuda R, Astudillo A, Vázquez F, De los Toyos JR, Méndez FJ. 2004. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect. Immun. 72:4534-4540. http://dx.doi.org/10.1128/IAI.72.8.4534-4540.2004. (Pubitemid 38989312)
67. Anderson R, Steel HC, Cockeran R, von Gottberg A, de Gouveia L, Klugman KP, Mitchell TJ, Feldman C. 2007. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J. Antimicrob. Chemother. 60:1155-1158. http://dx.doi.org/10.1093/jac/dkm338. (Pubitemid 47617770)
68. Berry AM, Paton JC, Hansman D. 1992. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb. Pathog. 12:87-93. http://dx.doi.org/10. 1016/0882-4010(92)90111-Z.
69. Sanchez-Puelles JM, Ronda C, Garcia JL, Garcia P, Lopez R, Garcia E. 1986. Searching for autolysin functions. Characterization of a pneumococcal mutant deleted in the lytA gene. Eur. J. Biochem. 158:289-293.
70. López R, García E, García P, García JL. 1997. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb. Drug Resist. 3:199-211. http://dx.doi.org/10.1089/mdr.1997.3. 199. (Pubitemid 27250971)
71. Natarajan G, Glibetic M, Raykova V, Ofenstein JP, Thomas RL, Aranda JV. 2007. Nitric oxide and prostaglandin response to group B streptococcal infection in the lung. Ann. Clin. Lab. Sci. 37:170-176. (Pubitemid 46717196)
72. Raykova VD, Glibetic M, Ofenstein JP, Aranda JV. 2003. Nitric oxide-dependent regulation of pro-inflammatory cytokines in group B streptococcal inflammation of rat lung. Ann. Clin. Lab. Sci. 33:62-67. (Pubitemid 36337000)